Lithium vs. Valproate in Residual Schizophrenia: Case Safety Signal
A 2026 case report described valproate 800 mg/day improving agitation in residual-phase treatment-resistant schizophrenia but being followed by hypoglycemia and pancytopenia; after discontin…
Read article